First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses. Association between ...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
In this thought leadership interview, Steffen Saltofte, Chief Executive Officer at Zentiva and President of Medicines for Europe, reflects on the progress made since the Draghi report set out a ...
(MENAFN- EIN Presswire) EINPresswire/ -- The global Anti-Vascular Endothelial Growth Factor (Anti-VEGF) market is poised for significant growth in the coming years. Valued at US$ 25.2 billion in 2025, ...
A long-standing debate over the most effective treatment for prevalent forms of colorectal cancer — the world’s third most diagnosed cancer — was finally settled in June 2022. The much-anticipated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results